Chapter: Pharmacology of Antiplatelet Drugs

Learning Objectives

By the end of this chapter, the student should be able to:

• define antiplatelet drugs
• explain the physiology of platelet activation and aggregation
• classify antiplatelet drugs
• describe the mechanism of action of major antiplatelet agents
• discuss their pharmacological actions, therapeutic uses, adverse effects, and contraindications
• distinguish antiplatelet drugs from anticoagulants
• answer common viva and theory questions on the topic

---

1. Introduction

Antiplatelet drugs are agents that inhibit platelet activation, adhesion, or aggregation, thereby preventing formation of platelet-rich arterial thrombi.

These drugs are especially important in diseases where platelet aggregation is central to pathogenesis, such as:

• myocardial infarction
• unstable angina
• ischemic stroke
• transient ischemic attack
• peripheral arterial disease
• post-coronary angioplasty and stenting

They are among the most frequently prescribed drugs in cardiovascular and cerebrovascular medicine.

---

2. Physiological Basis of Platelet Aggregation

To understand antiplatelet drugs, one must first understand how platelets participate in hemostasis.

2.1 Steps in platelet plug formation

When the endothelium is damaged:

1. Platelet adhesion occurs at the site of injury
   • mediated by von Willebrand factor
   • platelets adhere to exposed collagen
2. Platelet activation occurs
   • platelets change shape
   • granule contents are released
3. Release of mediators
   Activated platelets release:
   • ADP
   • serotonin
   • thromboxane A₂ (TXA₂)
4. Platelet aggregation
   • GP IIb/IIIa receptors are activated
   • fibrinogen binds adjacent platelets together
   • platelet plug is formed

2.2 Important mediators

Mediator	Action
ADP	promotes platelet activation and aggregation
Thromboxane A₂	causes platelet aggregation and vasoconstriction
Prostacyclin (PGI₂)	inhibits platelet aggregation and causes vasodilation
Nitric oxide	inhibits platelet activation
Thrombin	strong platelet activator
GP IIb/IIIa receptor	final receptor mediating platelet aggregation via fibrinogen binding

---

3. Definition and General Features

Antiplatelet drugs are used primarily to prevent arterial thrombosis, because arterial thrombi are rich in platelets.

This is in contrast to venous thrombi, which are more fibrin-rich and are more effectively treated with anticoagulants.

---

4. Classification of Antiplatelet Drugs

4.1 Main classification

Class	Drugs
Cyclooxygenase inhibitor	Aspirin
ADP (P2Y12) receptor antagonists	Clopidogrel, Prasugrel, Ticagrelor, Ticlopidine, Cangrelor
GP IIb/IIIa receptor antagonists	Abciximab, Eptifibatide, Tirofiban
Phosphodiesterase inhibitors / adenosine uptake inhibitors	Dipyridamole, Cilostazol
Others	specialized or less commonly used agents

---

5. Aspirin

5.1 Mechanism of action

Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) in platelets.

This prevents the formation of thromboxane A₂, which is a potent promoter of:

• platelet aggregation
• vasoconstriction

Because platelets have no nucleus, they cannot synthesize new COX enzyme. Therefore, aspirin inhibits platelet function for the entire life span of the platelet, which is about 7–10 days.

5.2 Pharmacological actions

• inhibits platelet aggregation
• prolongs bleeding time
• reduces arterial thrombus formation
• decreases risk of myocardial infarction and ischemic stroke

5.3 Therapeutic uses

• acute coronary syndrome
• unstable angina
• myocardial infarction
• secondary prevention after MI
• transient ischemic attack
• ischemic stroke prevention
• peripheral arterial disease
• after coronary stenting

5.4 Adverse effects

• gastric irritation
• nausea
• peptic ulceration
• gastrointestinal bleeding
• hypersensitivity
• bronchospasm in aspirin-sensitive patients
• bleeding tendency

5.5 Contraindications

• active peptic ulcer
• bleeding disorders
• aspirin hypersensitivity
• children with viral fever
• severe thrombocytopenia

---

6. ADP (P2Y12) Receptor Antagonists

These drugs inhibit ADP-mediated platelet activation by blocking the P2Y12 receptor.

This prevents activation of GP IIb/IIIa receptors and inhibits platelet aggregation.

---

6.1 Clopidogrel

Mechanism of action

Clopidogrel is a prodrug. After hepatic activation, it irreversibly blocks P2Y12 receptors on platelets.

Actions

• inhibits ADP-induced platelet aggregation
• prevents activation of GP IIb/IIIa receptors

Uses

• acute coronary syndrome
• recent myocardial infarction
• recent ischemic stroke
• peripheral arterial disease
• after PCI and stent placement
• aspirin intolerance

Adverse effects

• bleeding
• rash
• diarrhea
• rare thrombotic thrombocytopenic purpura

Important point

Clopidogrel requires activation by hepatic CYP enzymes, especially CYP2C19.

---

6.2 Prasugrel

Mechanism

Prasugrel is also a prodrug and irreversibly blocks the P2Y12 receptor.

Features

• faster onset than clopidogrel
• more potent platelet inhibition
• more predictable response

Uses

• acute coronary syndrome
• especially in patients undergoing PCI

Adverse effects

• bleeding, sometimes severe

Caution

Use carefully in:

• elderly patients
• low body weight
• previous stroke or TIA

---

6.3 Ticagrelor

Mechanism

Ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist.

Features

• does not require activation
• rapid onset
• reversible inhibition
• stronger antiplatelet action than clopidogrel in many settings

Uses

• acute coronary syndrome
• post-PCI
• dual antiplatelet therapy

Adverse effects

• bleeding
• dyspnea
• bradyarrhythmia
• increased uric acid in some cases

---

6.4 Ticlopidine

This is an older P2Y12 inhibitor.

Adverse effects

• neutropenia
• agranulocytosis
• TTP

Because of toxicity, it is now rarely used.

---

6.5 Cangrelor

Mechanism

Cangrelor is an intravenous, direct, reversible P2Y12 inhibitor.

Uses

• rapid platelet inhibition during cardiac interventions
• short-term hospital use

---

7. GP IIb/IIIa Receptor Antagonists

These drugs block the final common pathway of platelet aggregation.

Normally, activated GP IIb/IIIa receptors bind fibrinogen, which links platelets together. Blocking these receptors produces potent antiplatelet action.

Drugs in this class

• Abciximab
• Eptifibatide
• Tirofiban

---

7.1 Abciximab

Mechanism

Abciximab is a monoclonal antibody fragment that blocks GP IIb/IIIa receptors.

Uses

• during angioplasty
• selected acute coronary syndrome cases
• PCI

Adverse effects

• bleeding
• thrombocytopenia

---

7.2 Eptifibatide and Tirofiban

Mechanism

These drugs inhibit GP IIb/IIIa receptor-mediated fibrinogen binding and aggregation.

Uses

• acute coronary syndrome
• PCI

Adverse effects

• bleeding
• thrombocytopenia

---

8. Dipyridamole

8.1 Mechanism of action

Dipyridamole:

• inhibits phosphodiesterase
• inhibits adenosine uptake

This increases platelet cAMP, which suppresses platelet activation. It also causes vasodilation.

8.2 Uses

• prevention of stroke in combination with aspirin
• some selected cardiovascular uses
• pharmacologic stress testing

8.3 Adverse effects

• headache
• flushing
• dizziness
• hypotension
• palpitations

---

9. Cilostazol

9.1 Mechanism of action

Cilostazol is a phosphodiesterase III inhibitor.

It increases cAMP in:

• platelets → inhibits aggregation
• blood vessels → causes vasodilation

9.2 Uses

• intermittent claudication in peripheral arterial disease

9.3 Adverse effects

• headache
• palpitations
• tachycardia
• diarrhea

9.4 Contraindication

• heart failure

---

10. Summary Table of Major Antiplatelet Drugs

Drug/Class	Mechanism	Reversible/Irreversible	Main Uses	Major Adverse Effect
Aspirin	inhibits COX-1 → ↓ TXA₂	Irreversible	MI, stroke prevention, ACS	GI irritation, bleeding
Clopidogrel	blocks P2Y12 receptor	Irreversible	ACS, post-stent, stroke prevention	bleeding, rare TTP
Prasugrel	blocks P2Y12 receptor	Irreversible	ACS with PCI	bleeding
Ticagrelor	blocks P2Y12 receptor	Reversible	ACS, DAPT	bleeding, dyspnea
Cangrelor	blocks P2Y12 receptor	Reversible	IV use in interventions	bleeding
Abciximab	blocks GP IIb/IIIa	Functional prolonged effect	PCI, ACS	bleeding, thrombocytopenia
Eptifibatide	blocks GP IIb/IIIa	Reversible	ACS, PCI	bleeding
Tirofiban	blocks GP IIb/IIIa	Reversible	ACS, PCI	bleeding
Dipyridamole	↑ cAMP, ↓ platelet activation	Reversible	stroke prevention with aspirin	headache
Cilostazol	PDE III inhibition → ↑ cAMP	Reversible	intermittent claudication	tachycardia, headache

---

11. Dual Antiplatelet Therapy (DAPT)

Definition

Dual antiplatelet therapy means the use of:

Aspirin + one P2Y12 inhibitor

Examples:

• aspirin + clopidogrel
• aspirin + prasugrel
• aspirin + ticagrelor

Rationale

Since the drugs act through different mechanisms, combined use gives stronger inhibition of platelet aggregation.

Indications

• acute coronary syndrome
• after coronary stent placement
• post-myocardial infarction

Limitation

• increased risk of bleeding

---

12. Adverse Effects of Antiplatelet Drugs

The most important adverse effect of the whole group is:

12.1 Bleeding

This may manifest as:

• bruising
• epistaxis
• gum bleeding
• GI bleeding
• hematuria
• intracranial hemorrhage in severe cases

12.2 Drug-specific adverse effects

Drug	Characteristic adverse effect
Aspirin	gastritis, peptic ulcer, GI bleeding
Clopidogrel	rare TTP
Prasugrel	more severe bleeding
Ticagrelor	dyspnea
Abciximab	thrombocytopenia
Dipyridamole	headache, flushing
Cilostazol	palpitations, tachycardia

---

13. Contraindications and Precautions

Antiplatelet drugs should be used carefully in:

• active bleeding
• peptic ulcer disease
• hemorrhagic stroke
• severe thrombocytopenia
• uncontrolled hypertension
• before major surgery
• liver disease in some patients
• renal dysfunction for selected drugs

---

14. Antiplatelet Drugs versus Anticoagulants

This is a very important exam topic.

Feature	Antiplatelet Drugs	Anticoagulants
Main target	platelets	coagulation factors
Main use	arterial thrombosis	venous thrombosis, cardioembolic disease
Thrombus type	platelet-rich thrombi	fibrin-rich thrombi
Examples	aspirin, clopidogrel	heparin, warfarin, DOACs

Key concept

• Arterial thrombi are mainly platelet-rich
• Venous thrombi are mainly fibrin-rich

---

15. Clinical Uses of Antiplatelet Drugs

Cardiovascular uses

• unstable angina
• myocardial infarction
• acute coronary syndrome
• chronic coronary artery disease
• post-PCI
• post-coronary stenting

Cerebrovascular uses

• TIA
• ischemic stroke prevention

Peripheral vascular uses

• peripheral arterial disease
• intermittent claudication

---

16. Mnemonics

16.1 Aspirin mechanism

“Aspirin Abolishes A₂”
Aspirin abolishes thromboxane A₂

16.2 Clopidogrel class

“CLOP blocks CLOP of ADP”
Clopidogrel blocks the ADP receptor

16.3 Ticagrelor fact

“Tica is quick and reversible”
Ticagrelor = direct, fast, reversible

16.4 GP IIb/IIIa blockers

“ATE the fibrin bridge”

• Abciximab
• Tirofiban
• Eptifibatide

They stop the fibrinogen bridge between platelets.

16.5 Major toxicity

“All anti-platelets make you anti-clot, so bleeding is the blot”

16.6 DAPT

“A + P = Powerful Platelet Prevention”
Aspirin + P2Y12 inhibitor

---

17. High-Yield Exam Points

• Aspirin irreversibly inhibits COX-1 in platelets.
• Clopidogrel is a prodrug.
• Ticagrelor is reversible.
• GP IIb/IIIa blockers inhibit the final common pathway of platelet aggregation.
• Main adverse effect of antiplatelet drugs is bleeding.
• Antiplatelet drugs are mainly useful in arterial thrombosis.
• Cilostazol is used in intermittent claudication.
• Ticlopidine is rarely used because of bone marrow toxicity.
• Dual antiplatelet therapy is common after stent placement.

---

18. Viva Questions and Answers

Short viva questions

1. What are antiplatelet drugs?
Drugs that inhibit platelet activation and aggregation, thereby preventing arterial thrombus formation.

2. Why are antiplatelet drugs mainly used in arterial thrombosis?
Because arterial thrombi are rich in platelets.

3. Which is the most commonly used antiplatelet drug?
Aspirin.

4. How does aspirin act as an antiplatelet drug?
It irreversibly inhibits COX-1 in platelets and decreases thromboxane A₂ synthesis.

5. Why does aspirin act for 7–10 days?
Because platelets are anucleate and cannot synthesize new COX enzyme.

6. What is the receptor blocked by clopidogrel?
P2Y12 receptor.

7. Is clopidogrel a prodrug?
Yes.

8. Name a reversible P2Y12 inhibitor.
Ticagrelor.

9. Name an intravenous P2Y12 inhibitor.
Cangrelor.

10. Which drugs block GP IIb/IIIa receptors?
Abciximab, eptifibatide, and tirofiban.

11. Which antiplatelet drugs block the final common pathway?
GP IIb/IIIa antagonists.

12. Which drug is used for intermittent claudication?
Cilostazol.

13. What is the major adverse effect of antiplatelet drugs?
Bleeding.

14. Which old antiplatelet drug can cause neutropenia?
Ticlopidine.

15. What is dual antiplatelet therapy?
Combination of aspirin with a P2Y12 inhibitor.

---

Long viva questions

1. Classify antiplatelet drugs and describe the mechanism of action of each class.

2. Write a detailed note on aspirin as an antiplatelet drug.

3. Compare clopidogrel, prasugrel, and ticagrelor.

4. What are GP IIb/IIIa receptor antagonists? Discuss their uses and adverse effects.

5. Differentiate antiplatelet drugs from anticoagulants.

---

19. Short Notes for University Exams

Short note: Aspirin as antiplatelet drug

Aspirin irreversibly inhibits platelet COX-1 and prevents thromboxane A₂ formation. It inhibits platelet aggregation for the life span of the platelet. It is used in MI, ACS, stroke prevention, and post-stent states. Major adverse effects are GI irritation, ulceration, and bleeding.

Short note: Clopidogrel

Clopidogrel is a prodrug that irreversibly blocks P2Y12 receptors on platelets after hepatic activation. It inhibits ADP-mediated platelet aggregation. It is used in ACS, stroke prevention, PAD, and after stenting. Major adverse effect is bleeding; rare TTP may occur.

Short note: GP IIb/IIIa blockers

These drugs block the final common pathway of platelet aggregation by inhibiting fibrinogen binding to GP IIb/IIIa receptors. Drugs include abciximab, eptifibatide, and tirofiban. They are used intravenously in ACS and PCI. Main adverse effects are bleeding and thrombocytopenia.

---

20. One-Page Revision Table

Topic	Key Point
Main role	prevent platelet aggregation
Best for	arterial thrombosis
Most common drug	aspirin
Aspirin action	irreversible COX-1 inhibition
Clopidogrel	irreversible P2Y12 blocker, prodrug
Ticagrelor	reversible P2Y12 blocker
Final common pathway blockers	GP IIb/IIIa antagonists
Drug for intermittent claudication	cilostazol
Main toxicity	bleeding
DAPT	aspirin + P2Y12 inhibitor

---

21. Conclusion

Antiplatelet drugs are essential agents in the prevention and treatment of atherothrombotic disease. Their pharmacological basis lies in inhibition of key steps in platelet activation and aggregation, especially the TXA₂ pathway, ADP pathway, and GP IIb/IIIa-mediated fibrinogen binding. A good understanding of their classification, mechanism, uses, and toxicity is extremely important for MBBS students because these drugs are widely used in modern clinical practice.

---

22. Rapid Recall Box

• Aspirin → COX-1 inhibitor → ↓ TXA₂
• Clopidogrel / Prasugrel → irreversible P2Y12 blockers
• Ticagrelor → reversible P2Y12 blocker
• Abciximab / Eptifibatide / Tirofiban → GP IIb/IIIa blockers
• Dipyridamole / Cilostazol → ↑ cAMP → inhibit aggregation
• Main adverse effect → bleeding
• Main use → arterial thrombosis
• DAPT → aspirin + P2Y12 inhibitor